Article
Finerenone ameliorates diabetic renal fibrosis via KRAS/FOXM1/SEMA3C signaling pathway in mesangial cells
2025-12-11
Abstract excerpt
<h4>Background: </h4> and Purpose: Hyperactivation of the mineralocorticoid receptor (MR) causes pro-inflammatory and pro-fibrotic actions, which are potential therapeutic targets of diabetic kidney disease (DKD). Finerenone (FIN), a novel non-steroidal mineralocorticoid receptor antagonist, attenuates vascular endothelial cell fibrosis in diabetic kidneys, but the precise mechanism remains unclear. Present study...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d3bea3ef-cfb8-5ad4-ad8e-94e1069163f9
- DOI
- 10.22541/au.176545938.83190905/v1
